New hope to stop heart and kidney decline after critical illness
NCT ID NCT07025629
Summary
This study tests if a drug called dapagliflozin can protect the heart and kidneys of patients after they leave the intensive care unit (ICU). About 600 patients who were on life support in the ICU will take either the drug or a placebo pill daily for one year. Researchers will track if the drug reduces deaths, heart failure hospitalizations, and serious kidney decline over that time.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEART FAILURE AND CHRONIC KIDNEY DISEASE POST-ICU are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hospital Saint Louis
RECRUITINGParis, 75010, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Saint Louis Hospital
NOT_YET_RECRUITINGParis, 75010, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.